Reckitt Benckiser Group plc

Reckitt Benckiser Group plc

RBGLY
Reckitt Benckiser Group plcUS flagOther OTC
13.70
USD
-0.29
- -
43.50BMarket Cap
Reckitt Benckiser Group plc
RBGLY
(Other OTC)

Recent

price

13.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.43
2.72
2.75
2.69
2.55
2.59
2.8
3.4
3.72
3.78
4.1
3.86
4.21
4.25
4.21
4.36
2.72
Revenue per Share
0.45
0.5
0.52
0.5
0.93
0.51
0.54
1.83
0.64
-1.08
0.35
-0.01
0.68
0.48
0.42
0.98
0.5
Basic EPS, GAAP
0.34
0.44
0.49
0.55
0.55
0.47
0.6
0.64
0.62
0.28
0.89
0.36
0.57
0.64
0.66
0.52
0.5
Free Cash Flow per Basic Share
0.22
0.25
0.26
0.29
0.29
0.27
0.31
0.34
0.35
0.36
0.36
0.36
0.36
0.39
0.41
0.43
- -
Dividend per Share
5.44
5.65
5.78
6.03
6.25
6.38
6.47
8.04
8.34
6.89
6.88
6.59
6.91
6.83
6.56
7.2
5.67
Book Value per Share
-1.36
-1.28
-1.51
-1.39
-1.28
-1.28
-1.49
-4.73
-4.58
-4.37
-4.05
-3.33
-3.12
-2.94
-3.23
-2.46
-1.28
Tangible Book Value per Share
3,476
3,493
3,476
3,448
3,460
3,423
3,380
3,371
3,388
3,402
3,412
3,426
3,433
3,440
3,362
3,261
3,485
Basic Weighted Avg Shares
8,453
9,485
9,567
9,266
8,836
8,874
9,480
11,449
12,597
12,846
13,993
13,234
14,453
14,607
14,169
14,205
9,485
Sales/Revenue/Turnover
26.05
26.22
26.94
23.13
24.73
26.75
27.81
26.89
26.13
24.61
22.48
20.51
23.54
22.91
24.27
24.12
26.17
Operating Margin (%)
144
157
148
155
161
171
177
268
409
5,552
1,455
429
604
470
461
499
- -
Depreciation Expense
1,568
1,745
1,821
1,739
3,223
1,743
1,832
6,172
2,159
-3,683
1,187
-32
2,330
1,643
1,426
3,182
1,745
Net Income, GAAP
26.5
26.18
24.21
24.41
21.73
20.97
23.08
- -
19.71
- -
38.44
- -
23.18
31.36
31.94
16.55
26.18
Effective Tax Rate (%)
18.55
18.4
19.03
18.77
36.48
19.64
19.32
53.91
17.14
-28.67
8.48
-0.24
16.12
11.25
10.06
22.4
18.4
Profit Margin (%)
-3,099
-2,762
-3,406
-2,760
-2,129
-2,157
-1,951
-1,200
-2,717
-3,898
-1,624
-3,083
-3,056
-3,036
-3,345
-1,015
-2,762
Working Capital
3
3
3
598
636
671
804
11,797
9,950
8,545
9,794
7,078
7,163
6,858
7,235
7,620
3
LT Debt
5,130
5,781
5,922
6,336
6,834
6,906
8,426
13,557
14,771
9,407
9,159
7,453
9,483
8,469
6,720
7,781
5,781
Total Equity
25.46
21.92
21.67
17.21
17.97
19.6
19.89
- -
9.82
- -
9.28
- -
14.31
12.4
13.82
17.32
21.87
Return on Invested Capital (%)
7.91
8
8.12
7.53
13.64
7.33
7.7
- -
5.99
- -
3.85
- -
7.68
5.69
5.39
11.26
8.01
Return on Capital (%)
8.5
9.03
9.14
8.5
15.19
8.02
8.38
25.2
7.8
-14.25
5.06
-0.14
10.07
6.96
6.26
13.98
9.03
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jun'11
Sep'11
Dec'11
ST Debt
2,849
- -
2,505
LT Borrowings
3
- -
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
699
699
699
Market Capitalization
31,566
29,594
28,963

Working Capital

FRC

in mil. unless spec.
Jun'11
Sep'11
Dec'11
Total Current Assets
2,981
- -
2,938
Cash, Cash Equivalents & STI
581
- -
650
Accounts Receivable, Net
1,450
- -
1,247
Inventories
742
- -
758
Total Current Liabilities
6,191
- -
5,700
Payables & Accruals
- -
- -
- -
ST Debt
2,849
- -
2,505
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.6%
-1.39%
15.79%
Free Cash Flow
17.6%
-2.6%
-24.13%
Net Income, GAAP
-762.93%
-1,480.7%
123.14%
Sales/Revenue/Turnover
5.06%
0.42%
0.25%
Total Cash Common Dividend
4.33%
2.52%
1.59%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
14,607
2024
- -
- -
- -
- -
14,169
2025
- -
- -
- -
- -
14,205

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.48
2024
- -
- -
- -
- -
0.42
2025
- -
- -
- -
- -
0.98

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.39
2024
- -
- -
- -
- -
0.41
2025
- -
- -
- -
- -
0.43
Business
Reckitt Benckiser Group plc is a British multinational consumer goods company primarily engaged in the manufacture and sale of health, hygiene, and nutrition products. Founded through the merger of Reckitt & Colman plc and Benckiser NV in 1999, the company is headquartered in Slough, United Kingdom, and operates globally with products sold in nearly 200 countries. Reckitt organizes its business into three main segments: Health, Hygiene, and Nutrition. The Health segment offers over-the-counter (OTC) pharmaceuticals including pain relief, gastrointestinal and respiratory products, germ protection solutions, vitamins, minerals and supplements (VMS), intimate wellness, and personal care products. Its Hygiene segment includes categories such as surface and disinfection, auto dishwasher products, air care, fabric additives, and lavatory care. The Nutrition segment focuses on infant and child nutrition and specialized nutritional solutions. In recent major developments, Reckitt has embarked on a strategic overhaul to sharpen its portfolio focusing on high-growth, high-margin "Powerbrands" while planning to exit its Essential Home business, which includes several homecare brands, by the end of 2025. This strategy aims to simplify its organizational structure from a global business unit model to a unified category structure operating through three geographic regions: North America, Europe, and Emerging Markets. The company pursues operational efficiency with initiatives to reduce fixed costs by at least 300 basis points by 2027 and has announced a substantial £1 billion share buyback program. Reckitt continues investing in innovation and market execution while enhancing its supply chain resilience and R&D capabilities. Recent performance reflects resilience in Health and Hygiene segments despite challenging conditions, with management targeting accelerated growth and margin expansion through brand focus and efficiency improvements. Reckitt’s portfolio includes well-known global brands such as Dettol, Lysol, Finish, Vanish, Durex, Nurofen, and Strepsils. The company serves retail and fast-moving consumer goods (FMCG) markets worldwide through a global distribution network comprising 131 distribution and embellishment centers across 51 countries. Reckitt employs over 35,000 people worldwide and generated revenue of approximately $18 billion in 2024, maintaining a significant presence across key markets including the US, UK, Europe, and emerging markets. This strategic realignment positions Reckitt as a focused consumer health and hygiene leader with an emphasis on innovation, brand strength, and operational excellence.

Company News

APIChatGPT
  • Reckitt Benckiser: Cheap Again, I'm Going In

  • Reckitt Benckiser Bets on AI to Speed Innovation and Boost Growth

  • Swiss bank sees upside for Reckitt Benckiser though the Dettol and Durex owner needs to "rebuild trust"

  • Reckitt Benckiser Group plc (RBGLY) Q1 2026 Sales/Trading Call Transcript

  • Reckitt stock dips on Q1 miss: what's really ailing the health giant?

  • Reckitt's Like-for-Like Revenue Rises on Emerging Markets Performance

  • New Strong Sell Stocks for April 10th

  • Reckitt Benckiser: Cheap Again Amid Macro Concerns

  • Reckitt Benckiser Group (OTCMKTS:RBGLY) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

  • Reckitt Benckiser Group plc (RBGLY) Presents at UBS Global Consumer and Retail Conference Transcript

  • Reckitt not yet rewarded for improved earnings model, says UBS after strong quarter

  • Reckitt Core Brands Revenue Rises 5.2% as Turnaround Strategy Gains Momentum

  • Reckitt Benckiser Group plc (RBGLY) Q4 2025 Earnings Call Transcript

  • Reckitt beats its own targets and signals confidence in 2026 after year of strategic progress

  • Lysol Maker Reckitt Books Rise in Revenue, Boosted by Emerging Markets

  • Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Short Interest Update

  • Reckitt downgraded by RBC as Deutsche Bank strikes more bullish tone

  • Reckitt to pay £1.6bn special dividend after Essential Home sale

  • Avatars, influencers in China livestreams help drive Reckitt's emerging-market led growth

  • Reckitt Benckiser Group Plc. ADR (RBGLY) Focus On Emerging Markets: Growth Opportunities and Strategic Capabilities Discussion Transcript